PATENT CLAIM ANALYSIS

Application Number: 16414878
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-11
Patent Classification: ["514", "450000"]

Abstract:
A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

Claim (Index 5):
The method of  claim 1  wherein the patient is administered less than 40 mcg bryostatin-1.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 100.0
- Lexical Diversity: 1.28571
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14059529', '12538245', '12080756', '13642845', '14929731']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7221635032501094
- 35 USC 102 Novelty (BERT): 0.5091203015948876
- Combined Prediction Score: 0.7008591830845872
- Mean Citation Score: 215.540846
- Max Citation Score: 222.36365
- Similarity Product: 134.64218030085266

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test